Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Kunihito Gotoh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6890-6293; OpenAlex author ID A5103191262. Sources: OpenAlex.

Their work

Papers
39 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
86
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: 9 papers · 2018: 5 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 5 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 39

  1. Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative… Last author DOI 10.1002/ags3.70191↗
  2. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  3. Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis. Co-author DOI 10.1245/s10434-025-18659-x↗
  4. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  5. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  6. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00280-023-04531-w↗
  7. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. First author DOI 10.1007/s10147-023-02306-0↗
  8. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  9. The impact of cellular senescence and senescence‑associated secretory phenotype in cancer‑associated fibroblasts on the malignancy of pancreatic cancer. Co-author DOI 10.3892/or.2023.8535↗
  10. [A Case of Conversion Surgery after Long-Term Chemotherapy for Pancreatic Cancer with Peritoneal Metastasis]. First author PMID 36759995↗
  11. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
  12. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  13. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  14. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… Co-author DOI 10.1002/ags3.12418↗
  15. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.04.029↗
  16. Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes. Co-author DOI 10.1002/ags3.12326↗
  17. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Co-author DOI 10.1007/s00280-019-04005-y↗
  18. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-019-07927-2↗
  19. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cmdc.201900324↗
  20. Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2… Co-author DOI 10.1111/cas.13918↗
  21. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Co-author DOI 10.1007/s00595-018-1674-3↗
  22. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1159/000475477↗
  23. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Co-author DOI 10.1245/s10434-018-6431-8↗
  24. Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Co-author DOI 10.3892/ol.2018.8357↗
  25. The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8795↗
  26. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
  27. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
  28. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  29. Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000943↗
  30. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Co-author DOI 10.1111/cas.13159↗
  31. Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case … Co-author DOI 10.1186/s40792-017-0314-2↗
  32. CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-017-5914-3↗
  33. Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. Co-author DOI 10.1245/s10434-017-6040-y↗
  34. [A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy]. Co-author PMID 29394852↗
  35. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on opera… Co-author DOI 10.1016/j.surg.2014.09.022↗
  36. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy … Co-author DOI 10.1007/s00268-012-1775-x↗
  37. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0b013e31829b3ce4↗
  38. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based che… Co-author DOI 10.1097/sla.0b013e31823d813c↗
  39. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2011.03.001↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 29 shared papers, 2012–2024 · strength 2.69
  2. Hidetoshi Eguchi · 28 shared papers, 2012–2024 · strength 2.64
  3. Yoshifumi Iwagami · 23 shared papers, 2017–2024 · strength 2.27
  4. Hirofumi Akita · 15 shared papers, 2015–2026 · strength 2.24
  5. Daisaku Yamada · 24 shared papers, 2017–2024 · strength 2.17
  6. Tadafumi Asaoka · 23 shared papers, 2017–2024 · strength 2.02
  7. Hidenori Takahashi · 13 shared papers, 2011–2026 · strength 1.56
  8. Yoshito Tomimaru · 11 shared papers, 2017–2024 · strength 1.41
  9. Masahiro Tanemura · 15 shared papers, 2017–2023 · strength 1.36
  10. Yutaka Takeda · 11 shared papers, 2017–2021 · strength 0.78
  11. Kazuki Sasaki · 5 shared papers, 2022–2024 · strength 0.75
  12. Shinichiro Hasegawa · 4 shared papers, 2017–2026 · strength 0.63
  13. Masahiko Kubo · 3 shared papers, 2020–2026 · strength 0.56
  14. Reishi Toshiyama · 4 shared papers, 2017–2024 · strength 0.44
  15. Ryoji Takada · 2 shared papers, 2023–2026 · strength 0.36
  16. Masaki Mori · 5 shared papers, 2017–2018 · strength 0.31
  17. Ryu Kanzaki · 1 shared paper, 2026 · strength 0.27
  18. Yoji Kukita · 1 shared paper, 2026 · strength 0.27
  19. Jiro Okami · 1 shared paper, 2026 · strength 0.27
  20. Ayumu Asai · 3 shared papers, 2018–2022 · strength 0.27
  21. Katsunori Matsushita · 3 shared papers, 2018–2022 · strength 0.27
  22. Suguru Mitsufuji · 2 shared papers, 2022 · strength 0.27
  23. Hideshi Ishii · 3 shared papers, 2018–2022 · strength 0.26
  24. Takumi Kinomoto · 1 shared paper, 2026 · strength 0.24
  25. Kenji Ikezawa · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.